- Coordinator
- Technische Universitaet Wien, Austria
- Runs
- 1 January 2027 to 31 December 2030
- Status
- Running
- EU funding
- €4.5m
- Total cost
- —
- Partners
- 21 organisations in 9 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101311592
What the project is doing
In the project's own words, from its summary on CORDIS.
Traditionally, proteins have been categorized into two main structural classes: ordered and disordered. Large parts of the human proteome contain intrinsically disordered regions (IDRs), which are highly flexible and only sometimes adopt a distinct conformation upon interaction with a binding partner. IDRs are fundamental to intracellular signalling and protein interaction networks, particularly transcriptional regulation.
Dysregulation of these processes is strongly associated with diseases including cancer and neurodegenerative disorders. However, targeting IDRs is challenging because of their dynamic nature and the lack of well-defined binding pockets. IDR targets have therefore been largely underrepresented in the pharmaceutical industry and the competencies for characterizing and targeting IDRs are lacking. The aim of the FlexCAT doctoral training network (DN) is to equip a cohort of doctoral candidates (DCs) with unique expertise and knowledge in characterizing and targeting IDRs.
We aim to challenge and complement the limitations of classical small molecule approaches that were primarily developed to target druggable pockets within folded proteins. The DCs will carry out challenging research projects with the aim to assemble, expand, develop and apply novel approaches to understand and exploit disordered targets and IDRs. We will focus on utilizing β-catenin, a central therapeutic target and prime example of an IDR-related drug targeting challenge.
Alongside the individual research projects, the DCs will expand their knowledge and transferrable skills through a structured training program, including secondments and contributions from the non-academic sector. The outcome of the FlexCAT DN will be increased understanding of the role of disordered targets and IDRs, their implications in disease and particularly cancer, while also developing practical strategies for exploring the therapeutic intervention of alternative IDR-related protein targets.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Technische Universitaet Wien | Wien | Austria | Coordinator |
| Boehringer Ingelheim Rcv GmbH & Co Kg | Wien | Austria | Associatedpartner |
| Medizinische Universitat Graz | Graz | Austria | Participant |
| Georg-August-Universitat Gottingen Stiftung Offentlichen Rechts | Gottingen | Germany | Participant |
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH | Neuherberg | Germany | Participant |
| Julius-Maximilians-Universitat Wurzburg | Wuerzburg | Germany | Participant |
| Technische Universitaet Muenchen | Muenchen | Germany | Associatedpartner |
| The Hebrew University of Jerusalem | Jerusalem | Israel | Participant |
| Istituto Europeo Di Oncologia SRL | Milano | Italy | Associatedpartner |
| Universita Degli Studi Di Milano | Milano | Italy | Participant |
| Universite Du Luxembourg | Esch-Sur-Alzette | Luxembourg | Participant |
| EnzyTag BV | Nuth | Netherlands | Associatedpartner |
| Figlinq B.V. | Amsterdam | Netherlands | Associatedpartner |
| Prinses Maxima Centrum Voor Kinderoncologie BV | Utrecht | Netherlands | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Stichting Oncode Institute | Utrecht | Netherlands | Associatedpartner |
| Universiteit Utrecht | Utrecht | Netherlands | Associatedpartner |
| Universiteit Van Amsterdam | Amsterdam | Netherlands | Associatedpartner |
| Direktoratet for Medisinske Produkter | Oslo | Norway | Associatedpartner |
| The University of Sussex | Brighton | United Kingdom | Participant |
| Genentech Inc | South San Francisco Ca | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI